Drug trial tracks Long-Term safety for patients with rare immune diseases
NCT ID NCT06990529
Summary
This study is a follow-up for patients with rare, inherited immune system disorders who were in a previous trial of the drug leniolisib. It aims to check the long-term safety and side effects of continued treatment. Researchers will also monitor if the drug helps control disease symptoms like lung problems and enlarged organs over a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIDS LINKED TO PI3K are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IIS La Fe
RECRUITINGValencia, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lahey Hospital & Medical Center
RECRUITINGBurlington, Massachusetts, 01805, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.